A Phase II Study of TACE Plus PD-1 Antibody in the Locally Advanced Stomach Adenocarcinoma
Status:
Not yet recruiting
Trial end date:
2025-03-01
Target enrollment:
Participant gender:
Summary
This study is a phase II, prospective, single-center, single-arm trial to evaluate the
efficacy and safety of the combination of neoadjuvant transcatheter arterial
chemoembolization (TACE) and PD-1 antibody Tislelizumab in the locally advanced stomach
adenocarcinoma. The primary purpose of this study is to evaluate the pathologic complete
response (pCR) rate of TACE plus Tislelizumab. The second purpose is to evaluate pathologic
response rate (pRR), objective Response Rate (ORR), overall survival (OS) and
progression-free survival (PFS) of the patients enrolled in this study.